Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics

Travere Therapeutics, Inc. (TVTX): $7.17

0.07 (-0.97%)

POWR Rating

Component Grades








Add TVTX to Watchlist
Sign Up

Industry: Biotech




#228 of 351

in industry

TVTX Price/Volume Stats

Current price $7.17 52-week high $17.73
Prev. close $7.24 52-week low $5.12
Day low $7.02 Volume 815,200
Day high $7.24 Avg. volume 1,211,630
50-day MA $6.54 Dividend yield N/A
200-day MA $7.97 Market Cap 545.84M

TVTX Stock Price Chart Interactive Chart >

Travere Therapeutics, Inc. (TVTX) Company Bio

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.

TVTX Latest News Stream

Event/Time News Detail
Loading, please wait...

TVTX Latest Social Stream

Loading social stream, please wait...

View Full TVTX Social Stream

Latest TVTX News From Around the Web

Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU). Classical HCU is a rare genetic

Yahoo | December 14, 2023

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgAN to full approval Following engagement with the FDA on the two-year results from the Phase 3 DUPLEX Study in FSGS, Company conducting additional analyses of FSGS data and plans to re-engage FDA in 2024 Company is implementing a strategic reorganization to further focus near-term resources on ongoing FI

Yahoo | December 4, 2023

Travere Therapeutics (NASDAQ:TVTX) shareholders have endured a 74% loss from investing in the stock three years ago

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...

Yahoo | December 3, 2023

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET. A live webcast will be accessible on the Investor page of Travere’s website at, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for li

Yahoo | November 21, 2023

Travere Therapeutics Reports Third Quarter 2023 Financial Results

Received 430 new patient start forms for FILSPARI® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI totaled $8 million for the third quarter of 2023 Phase 3 PROTECT and DUPLEX Studies of sparsentan presented as ASN Kidney Week Late Breakers and simultaneously published in The Lancet and NEJM, respectively Completed sale of bile acid product portfolio for up to $445 million including potential future milestone-based payments, adv

Yahoo | November 7, 2023

Read More 'TVTX' Stories Here

TVTX Price Returns

1-mo 18.32%
3-mo -0.14%
6-mo -17.78%
1-year -58.55%
3-year -53.32%
5-year N/A
YTD -20.24%
2023 -57.25%
2022 -32.25%
2021 13.89%
2020 91.94%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!